Featured Content

FDA increases enforcement, policy steps against unproven stem cell therapies

Friday, September 1, 2017

Scott Gottlieb, M.D., the Commissioner of the FDA, has stated that the agency is beginning to enforce stricter and more aggressive tactics against stem cell clinics who are marketing and administrating unproven therapies to patients. The administration will work toward cracking down on companies who claim to have cures or treatments for diseases that have no conclusive clinical efficacy.

[Read More]

Integrated delivery of CRO services

Friday, September 1, 2017

Unified delivery of a broad range of services by a CRO within a single clinical trial can be difficult to do as each role within a CRO—be it a Clinical, Data or Laboratory Project Manager, is primarily focused on delivery of their own aspects of the trial.

[Read More]

Three Questions: Bill Row, Icon

Friday, September 1, 2017

CWWeekly presents this biweekly feature as a spotlight on issues that executives in clinical research face. This week, writer Sony Salzman spoke with Bill Row, MBA, MS, divisional principal, Real World Evidence, Commercialization & Outcomes, at Icon. His focus is commercial applications of real-world evidence late phase studies for both pharmaceutical companies and CROs.

[Read More]

Is eConsent adoption poised to grow?

Friday, September 1, 2017

Activity in the eConsent sector has risen considerably during the past six months, with Medidata’s acquisition of electronic informed consent pioneer Mytrus and the entry of new market players, even though widespread industry adoption of the technology has appeared to have stalled.

[Read More]

Site selection a continuing conundrum

Friday, September 1, 2017

For many companies, searching for clinical trial sites begins with a look at paper-based and spreadsheet tools that document where they had held earlier trials. Returning to familiar sites allows clinical trial teams to work with principal investigators with whom they have built relationships over time.

[Read More]

The CenterWatch Monthly Industry Close-Up, September 2017

Friday, September 1, 2017

In 2017, 13% of cancer diagnosed in adults will be rare cancers. Of those, prostate cancer represents 9.6% in the U.S. Prostate cancer is the second most common cancer and the second leading cause of cancer-related death in men in the U.S. According to the National Center for Health Statistics, approximately $11.9 billion is spent each year in the U.S. on prostate cancer treatment.

[Read More]